ICN Increases Stake in Syncor International
ICN Pharmaceuticals has boosted its stake in Syncor International Corp., a Chatsworth maker of radiopharmaceuticals, by more than 1% to 6.5%, according to a filing with the Securities and Exchange Commission.
Between May 5 and June 10, ICN bought 110,500 shares of Syncor common stock at $4.75 to $6.85 each. ICN, based in Costa Mesa, now holds 678,000 shares of Syncor common stock.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
